RT234-PAH
Pulmonary Arterial Hypertension (PAH) - acute symptom relief
Phase 2BActive
Key Facts
Indication
Pulmonary Arterial Hypertension (PAH) - acute symptom relief
Phase
Phase 2B
Status
Active
Company
About Respira Therapeutics
Respira Therapeutics, founded in 2013 and based in Albuquerque, New Mexico, is a private, clinical-stage biotech focused on innovative inhaled drug delivery. The company's core technology platform combines specialized particle formulation with proprietary devices to target the deep lung, aiming to improve therapeutic outcomes for serious respiratory and cardiovascular conditions. Its lead candidate, RT234-PAH, is in Phase 2B trials for the acute relief of PAH symptoms, positioning the company in a significant unmet medical need. Respira operates as a pre-revenue, platform-based therapeutics company advancing a targeted pipeline.
View full company profile